DRTS — Alpha Tau Medical Income Statement
0.000.00%
- $185.80m
- $131.77m
- 35
- 20
- 60
- 31
Annual income statement for Alpha Tau Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.24 | 13.8 | 32.1 | 35.7 | 36 |
Operating Profit | -9.24 | -13.8 | -32.1 | -35.7 | -36 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.72 | -27.3 | -33.7 | -29.1 | -31.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.88 | -27.3 | -33.8 | -29.2 | -31.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.88 | -27.3 | -33.8 | -29.2 | -31.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.88 | -27.3 | -33.8 | -29.2 | -31.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.13 | -0.398 | -0.531 | -0.42 | -0.454 |
Dividends per Share |